CN105324385A - Bace抑制剂 - Google Patents

Bace抑制剂 Download PDF

Info

Publication number
CN105324385A
CN105324385A CN201480034958.0A CN201480034958A CN105324385A CN 105324385 A CN105324385 A CN 105324385A CN 201480034958 A CN201480034958 A CN 201480034958A CN 105324385 A CN105324385 A CN 105324385A
Authority
CN
China
Prior art keywords
fluoro
compound
solution
mixture
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480034958.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·格林
E·J·亨布雷
D·J·梅戈特
Y·史
B·M·沃森
L·L·小温纳罗斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN105324385A publication Critical patent/CN105324385A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480034958.0A 2013-06-18 2014-06-11 Bace抑制剂 Pending CN105324385A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361836175P 2013-06-18 2013-06-18
US61/836,175 2013-06-18
US201361877373P 2013-09-13 2013-09-13
US61/877,373 2013-09-13
PCT/US2014/041825 WO2014204730A1 (en) 2013-06-18 2014-06-11 Bace inhibitors

Publications (1)

Publication Number Publication Date
CN105324385A true CN105324385A (zh) 2016-02-10

Family

ID=51059662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480034958.0A Pending CN105324385A (zh) 2013-06-18 2014-06-11 Bace抑制剂

Country Status (14)

Country Link
US (2) US9029367B2 (cg-RX-API-DMAC10.html)
EP (1) EP3010925B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016522254A (cg-RX-API-DMAC10.html)
KR (1) KR101780140B1 (cg-RX-API-DMAC10.html)
CN (1) CN105324385A (cg-RX-API-DMAC10.html)
AU (1) AU2014281032B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015029348A8 (cg-RX-API-DMAC10.html)
CA (1) CA2910415C (cg-RX-API-DMAC10.html)
EA (1) EA027880B1 (cg-RX-API-DMAC10.html)
ES (1) ES2657905T3 (cg-RX-API-DMAC10.html)
JO (1) JO3318B1 (cg-RX-API-DMAC10.html)
MX (1) MX2015017156A (cg-RX-API-DMAC10.html)
TW (1) TWI639607B (cg-RX-API-DMAC10.html)
WO (1) WO2014204730A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109121412A (zh) * 2016-05-20 2019-01-01 伊莱利利公司 N-[3-[2-氨基-5-(1,1-二氟乙基)-4,4a,5,7-四氢呋喃并[3,4-d][1,3]噁嗪-7a-基]-4-氟-苯基]-5-(三氟甲基)吡啶-2-甲酰胺及其(4aR,5S,7aS)异构体作为选择性BACE1抑制剂用于治疗如阿尔茨海默病的用途
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种(1-氟环丙基)甲胺盐酸盐的制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 H 朗德貝克公司 包括給予2-胺基-3,5,5-三氟-3,4,5,6-四氫吡啶的聯合治療
RU2018104868A (ru) 2015-08-12 2019-09-13 Х. Лундбекк А/С 2-амино-3-фтор-3-(фторметил)-6-метил-6-фенил-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1
JP2018527338A (ja) * 2015-08-12 2018-09-20 ハー・ルンドベック・アクチエゼルスカベット BACE1阻害剤としての2−アミノ−7a−フェニル−3,4,4a,5,7,7a−ヘキサヒドロフロ[3,4−b]ピリジン
JP6889466B2 (ja) * 2016-12-09 2021-06-18 学校法人 名城大学 アミド基を含む単離された化合物の塩、その製造方法及びこれを用いたアミド化合物の合成方法
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910143A (zh) * 2008-01-18 2010-12-08 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
WO2011009898A1 (en) * 2009-07-22 2011-01-27 Eisai R&D Management Co., Ltd Fused aminodihydro-oxazine derivatives
CN102015667A (zh) * 2008-05-02 2011-04-13 伊莱利利公司 作为用于治疗阿尔茨海默氏病的bace抑制剂的氨基二氢噻嗪衍生物
CN102471296A (zh) * 2009-07-09 2012-05-23 伊莱利利公司 Bace抑制剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2537898T3 (es) 2005-10-25 2015-06-15 Shionogi & Co., Ltd. Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8637504B2 (en) 2008-06-13 2014-01-28 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity
KR20110076965A (ko) 2008-09-30 2011-07-06 에자이 알앤드디 매니지먼트 가부시키가이샤 신규한 축합 아미노 디하이드로티아진 유도체
US20120245154A1 (en) 2009-12-09 2012-09-27 Shionogi & Co., Ltd. Substituted aminothiazine derivative
US20120245155A1 (en) 2009-12-11 2012-09-27 Shionogi & Co., Ltd. Fused heterocyclic compound having amino group
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
RU2012129168A (ru) 2009-12-11 2014-01-20 Сионоги Энд Ко. Лтд. Производные оксазина
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2665716B1 (en) 2011-01-21 2017-03-08 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
TW201302763A (zh) 2011-05-24 2013-01-16 必治妥美雅史谷比公司 用於減少β-類澱粉產生之化合物
EP2718287A1 (en) 2011-06-07 2014-04-16 F.Hoffmann-La Roche Ag [1,3]oxazines
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
HUE053745T2 (hu) 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
HUE030534T2 (hu) 2012-04-27 2017-05-29 Eisai R&D Man Co Ltd Eljárás 5-(difluormetil)pirazin-2-karbonsav elõállítására és elõállítási intermediere
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101910143A (zh) * 2008-01-18 2010-12-08 卫材R&D管理有限公司 稠合的氨基二氢噻嗪衍生物
CN102015667A (zh) * 2008-05-02 2011-04-13 伊莱利利公司 作为用于治疗阿尔茨海默氏病的bace抑制剂的氨基二氢噻嗪衍生物
CN102471296A (zh) * 2009-07-09 2012-05-23 伊莱利利公司 Bace抑制剂
WO2011009898A1 (en) * 2009-07-22 2011-01-27 Eisai R&D Management Co., Ltd Fused aminodihydro-oxazine derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109121412A (zh) * 2016-05-20 2019-01-01 伊莱利利公司 N-[3-[2-氨基-5-(1,1-二氟乙基)-4,4a,5,7-四氢呋喃并[3,4-d][1,3]噁嗪-7a-基]-4-氟-苯基]-5-(三氟甲基)吡啶-2-甲酰胺及其(4aR,5S,7aS)异构体作为选择性BACE1抑制剂用于治疗如阿尔茨海默病的用途
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种(1-氟环丙基)甲胺盐酸盐的制备方法

Also Published As

Publication number Publication date
JO3318B1 (ar) 2019-03-13
TWI639607B (zh) 2018-11-01
CA2910415A1 (en) 2014-12-24
EA201592183A1 (ru) 2016-05-31
TW201536793A (zh) 2015-10-01
ES2657905T3 (es) 2018-03-07
KR20160009052A (ko) 2016-01-25
EP3010925B1 (en) 2017-10-04
EA027880B1 (ru) 2017-09-29
KR101780140B1 (ko) 2017-09-19
BR112015029348A8 (pt) 2020-03-17
AU2014281032A1 (en) 2015-11-12
US9029367B2 (en) 2015-05-12
MX2015017156A (es) 2016-03-16
BR112015029348A2 (pt) 2017-07-25
US20140371212A1 (en) 2014-12-18
EP3010925A1 (en) 2016-04-27
JP2016522254A (ja) 2016-07-28
US20150210716A1 (en) 2015-07-30
US9169271B2 (en) 2015-10-27
CA2910415C (en) 2017-09-05
WO2014204730A1 (en) 2014-12-24
AU2014281032B2 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
TWI639607B (zh) Bace抑制劑
JP4914348B2 (ja) C型肝炎インヒビターペプチド類似体
JP4748912B2 (ja) アルキルおよびアリールアラニンp2部分を含むc型肝炎ウイルスに対する大員環ns3−セリンプロテアーゼ阻害剤
JP6349360B2 (ja) Cb2アゴニストとして有用なピリジン−2−アミド
CN103159760B (zh) 作为cftr调控剂的氮杂吲哚衍生物
ES2323159T3 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
ES2349328T3 (es) Nuevos compuestos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
TWI283240B (en) VLA-4 inhibitor compounds
US5340802A (en) Peptide analog type-B CCK receptor ligands
JPH06293794A (ja) スルファモイル基およびアミジノ基を有する化合物、製造方法および医薬組成物
TW200539889A (en) (1R,2s,5s)-n-[(1s)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2s)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis c virus ns3/ns4a serine proteas
TW200902044A (en) Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2231279T3 (es) Compuesto con propiedades de liberacion de la hormona del crecimiento.
WO2023221975A1 (zh) 包含蛋白降解剂类生物活性化合物的抗体药物偶联物及其制备方法和用途
JP2005522430A (ja) グランザイムb阻害剤
CN1387526A (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN101921267A (zh) β-内酰胺后叶加压素V1a拮抗剂
JPH02256658A (ja) アミノ酸誘導体
JP7385852B2 (ja) P2x3受容体のアンタゴニストとしてのn-カルボキサミドピラゾリン系誘導体及びその使用
JP2009503027A (ja) アルツハイマー病iiの治療のための置換エタン−1,2−ジアミン
US6673784B1 (en) Electrophilic ketones for the treatment of herpesvirus infections
CN109715609A (zh) 环己基苯甲酰胺化合物
JPH04234842A (ja) トリフルオロメチルメルカプタンおよびメルカプトアシル誘導体
JPH11503450A (ja) C−末端アミネルジックな側鎖アミノ酸残基を含む血小板凝集抑制物質
CN107257795A (zh) 选择性bace1抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160210

WD01 Invention patent application deemed withdrawn after publication